Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes

ADOCIA announced today positive pharmacodynamic and safety topline results from the Phase 1 study of BioChaperone® Pramlintide Insulin (BC Pram Ins), the ready-to-use co-formulation of pramlintide and human insulin. The proprietary BioChaperone® technolo https://www.businesswire.com/news/home/20180905005695/en/Adocia-announces-positive-topline-results-clinical-study